Neostigmine Pharmacokinetics and Clinical Implications

Introduction to Neostigmine

Neostigmine has a half-life of 15-30 minutes when administered intravenously, according to the American Society of Anesthesiologists 1

Neostigmine is a quaternary ammonium compound that functions as a reversible acetylcholinesterase inhibitor, as stated by the American College of Clinical Pharmacology 2
The elimination half-life of neostigmine ranges from 15 to 30 minutes following intravenous administration, as reported by the American Society of Anesthesiologists 1

Neostigmine's relatively short half-life makes it suitable for reversing non-depolarizing neuromuscular blockade in anesthesia, according to the American Society of Anesthesiologists 2
The standard dose of neostigmine for reversal of neuromuscular blockade is 40-50 mcg/kg of ideal body weight, as recommended by the American College of Clinical Pharmacology 2
Due to its relatively short half-life, neostigmine should only be administered when there are at least 4 responses to train-of-four stimulation, as suggested by the American Society of Anesthesiologists 2, 3

Quantitative monitoring should continue after administration until a TOF ratio ≥0.9 is achieved, as recommended by the American College of Clinical Pharmacology 2
An anticholinergic agent (atropine or glycopyrrolate) should be administered with neostigmine to prevent cholinergic side effects due to its short half-life and rapid onset of action, according to the American Society of Anesthesiologists 2

IV neostigmine is the standard formulation used in anesthesia for reversal of neuromuscular blockade at doses of 40-50 mcg/kg of ideal body weight, as recommended by the American Society of Anesthesiologists 4, 5

IV neostigmine impairs upper airway patency by increasing airway closing pressure and reducing genioglossus muscle activity, according to the American Academy of Anesthesiologists 4, 6, 7
Do not administer IV neostigmine in the absence of residual neuromuscular blockade, as this causes paradoxical muscle weakness and respiratory impairment, as stated by the American Society of Anesthesiologists 4, 7, 5

Avoid giving neostigmine when TOF ratio >0.9, as this can decrease neuromuscular transmission and induce TOF fade lasting 17-53 minutes, as warned by the American Academy of Anesthesiologists 6, 7
The 40-50 mcg/kg IV dose exhibits a ceiling effect—increasing beyond 50 mcg/kg provides minimal additional benefit but increases side effects, according to the American Society of Anesthesiologists 4, 6, 8